deltatrials
Completed PHASE3 NCT00034879

Iressa Expanded Access Program (EAP)

An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Sponsor: AstraZeneca

Conditions Carcinoma Metastases Neoplasm Non-small-cell Lung
Interventions ZD1839 (Gefitinib)
Updated 7 times since 2017 Last updated: Jan 3, 2013 Started: Aug 31, 2000 Primary completion: Oct 31, 2003 Completion: Oct 31, 2003

A PHASE3 clinical study on Carcinoma and Metastases, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Aug 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States, Abilene, United States, Abington, United States, Akron, United States, Alabaster, United States, Albany, United States, Albuquerque, United States, Alexandria, United States, Allentown, United States, Amarillo, United States and 586 more location s